Volkan Niyazi Demircan

Dr. Volkan Niyazi Demircan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in World Neurosurgery
Verified
Journal Article
Closed access
OEOzge Petek Erpolat
Ozge Petek Erpolat
VDVolkan Niyazi Demircan
Volkan Niyazi Demircan
GSGulistan Sanem Sarıbas
Gulistan Sanem Sarıbas
PKPelin Kuzucu
Pelin Kuzucu
ESErtugrul Senturk
Ertugrul Senturk
GKGokhan Kurt
Gokhan Kurt

1 January 2024 in European Journal of Breast Health
Verified
Journal Article
Closed access
VDVolkan Niyazi Demircan
Volkan Niyazi Demircan
NBNuran Bese
Nuran Bese
Breast cancer stands as the most prevalent malignancy, necessitating a well-established approach to its management due to its sustained prevalence over decades. The implementation of intensive treatments, combining various modalities, has yielded excellent survival outcomes. Consequently, the optimization of quality of life and the mitigation of long-term side effects emerge as critical considerations for clinicians. As a result, discussions regarding treatment de-intensification strategies have been initiated for all treatment modalities, including surgery, radiotherapy (RT), and chemotherapy. RT plays a crucial role in adjuvant therapy. The efficacy of RT in disease control and overall survival across all stages of breast cancer has been demonstrated in numerous clinical trials and meta-analyses utilizing extensive datasets. However, advancements in genetic tumor profiling and improved identification of disease subgroups have prompted a reevaluation of RT omission in low-risk groups as a strategy for treatment de-intensification. Conversely, technological improvements and shortened total treatment times with hypofractionation make RT a secure and feasible option for enhancing local control and survival with minimal impact on the quality of life.

23 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VDVolkan Niyazi Demircan
Volkan Niyazi Demircan
CGCaglar Guzel
Caglar Guzel
GSGulistan Sanem Sarıbas
Gulistan Sanem Sarıbas
SDSerap Catlı Dinc
Serap Catlı Dinc
SCSerhat Cetin
Serhat Cetin
HBHuseyin Bora
Huseyin Bora
Radiation-induced renal fibrosis (RIRF) is a progressive, irreversible condition causing chronic kidney disease. Pentoxifylline (PTX) and vitamin E may mitigate radiation-induced damage and fibrosis. This study assesses their effectiveness. We used four groups, each with six rats: radiation therapy alone (RT-only), radiation therapy plus drug treatment (RT + drug), drug treatment alone (drug-only), and a control group. Rats were monitored for three months, with weight measurements every four weeks. Afterward, rats were analyzed biochemically and histologically, with blood and tissue samples taken for statistical comparison. No significant differences in serum creatinine levels and body weight were observed. RT-only group had more severe kidney tubule effects. Histomorphological, immunohistochemical, and TUNEL analyses showed significant RIRF mitigation in the RT + drug group. Our study highlighted molecular pathways (SMAD, TGF-beta, VEGF) and histological markers (collagens, a-SMA, fibronectin, metalloproteinases) associated with RIRF. PTX and vitamin E reduced ionizing radiation's impact on renal cells and mitigated radiation-induced kidney fibrosis. Further human studies are needed to confirm these findings.


14 October 2025
Verified
Book Chapter
Open access
PDF file
VDVolkan Niyazi Demircan
Volkan Niyazi Demircan
Stereotactic Body Radiation Therapy (SBRT) represents a paradigm shift in the radiotherapeutic management of lung tumors. With its ability to deliver high doses of radiation with sub-millimeter accuracy over a limited number of fractions, SBRT has significantly improved local control while minimizing toxicity to surrounding normal tissues. Initially employed in patients with early-stage non-small cell lung cancer (NSCLC) who were medically inoperable, SBRT is now widely accepted as a standard treatment in selected operable cases and has been increasingly utilized for treating pulmonary metastases from extrapulmonary primaries. This chapter aims to provide an overview of SBRT for lung tumors, focusing on technical considerations, clinical outcomes, and future perspectives.

5 May 2026 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
VDVolkan Niyazi Demircan
Volkan Niyazi Demircan
EŞErtuğrul Şentürk
Ertuğrul Şentürk
ETEvrim Tezcanlı
Evrim Tezcanlı
PEPetek Erpolat
Petek Erpolat
ZAZüleyha Akgün
Züleyha Akgün
BABanu Atalar
Banu Atalar
Purpose: The optimal timing of radiotherapy (RT) in patients with WHO grade 2 meningiomas remains controversial, particularly following gross total resection (GTR). This multicenter study compared long-term outcomes of early RT versus late RT, focusing on progression-free survival (PFS), overall survival (OS), and tumor-related mortality. Methods and materials: This retrospective multicenter cohort study included 263 adult patients with histopathologically confirmed WHO grade 2 meningiomas treated between 2005 and 2023. Patients were stratified by RT timing: early adjuvant RT after initial surgery versus late RT administered after radiologic or clinical progression. Outcomes were analyzed in the overall cohort and in a prespecified GTR subgroup. PFS and OS were estimated using the Kaplan–Meier method. Tumor-related mortality was assessed using cause-specific Cox and Fine–Gray competing-risk models. Results: With a median follow-up exceeding 7 years, early RT was associated with a significant improvement in PFS compared with late RT. In the overall cohort, 10-year PFS was 84.8% with early RT versus 18.6% with late RT ( p < 0.001). Among patients undergoing GTR, 10-year PFS remained high with early RT (89.3%) but declined markedly after late RT (18.8%; p < 0.001). RT timing was the strongest independent predictor of PFS in multivariable models, although its effect attenuated over time. Tumor-related mortality was approximately sixfold higher in the late RT group (16.7% vs 2.7%; p = 0.011), whereas all-cause mortality did not differ significantly (24.2% vs 14.7%; p = 0.198). Mitotic count and Ki-67 index were independently associated with early and long-term PFS, whereas male sex, older age, and subtotal resection predicted tumor-related mortality. Conclusions: Early RT provides a durable and clinically meaningful PFS benefit over late RT in WHO grade 2 meningiomas, including after GTR, without conferring an OS advantage. These findings emphasize the importance of RT timing and tumor biology in postoperative risk stratification and support consideration of early RT in selected patients, pending results from randomized trials.